|
|
|
|
|
|
|
|
|
|
UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement | ProteoMonitor | Proteomics | GenomeWeb
"... Vermillion had been developing OVA2 in collaboration with Zhen Zhang, a professor at Johns Hopkins University, and Daniel Chan, professor and director of the university's Biomarker Discovery Center. The company aimed to identify new biomarkers that could enhance the overall positive predictive value and specificity of the OVA1 ovarian cancer panel, potentially allowing it to move into broader fields of use such as screening of symptomatic and at-risk women...."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.